1990—2019年中国中枢神经系统肿瘤疾病负担变化趋势

目的 分析1990—2019年中国中枢神经系统(Brain and Central Nervous System, CNS)肿瘤疾病负担变化趋势。方法 检索2019年全球疾病负担数据库，提取中国CNS肿瘤的发病、患病、死亡、伤残调整寿命年(DALY)、早死损失寿命年(YLL)、伤残损失寿命年(YLD)数据，利用Excel、Joinpoint Regression Program 4.9.0.1统计分析中国1990—2019年CNS肿瘤的整体疾病负担变化趋势。结果 2019年中国CNS肿瘤发病人数为9.47万例，患病人数为32.79万例，死亡人数为9.22万例，YLL为201.62万人年，YLD为3.72万人年，DALY为205.34万人年。1990—2019年标化发病率、标化患病率、标化YLD率呈上升趋势(AAPC分别为0.84%、3.59%、1.88%,P<0.001),标化死亡率、标化YLL率、标化DALY率整体变化呈下降趋势(AAPC分别为-0.37%、-0.84%、-0.81%,P<0.001)。CNS肿瘤高年龄组(65～89岁)发病率呈上升趋势(AAPC=1.02...

Trend of the burden of Central Nervous System Cancer in China, 1990-2019

Objective To analyze the trend of the burden of central nervous system (CNS) cancer in China from 1990 to 2019. Methods We collected CNS cancer data of incidence, prevalence, death, DALY, YLL and YLD in China from 2019 Global Burden of Disease study. Excel and Joinpoint Regression Program 4.9.0.1 were used to calculate the time trend of disease burden of CNS cancer in China between 1990 and 2019. Results In 2019, there were 94700 incident cases, 327900 prevalent cases, 92200 death cases in China. The number of YLL was 2016200 person-years, the YLD was 37200 person-years, and the DALY was 2053400 person-years. From 1990 to 2019, its age-standardized incidence rate, age-standardized prevalence rate and age-standardized YLD rate showed an increasing trend (AAPC values were 0.84%, 3.59%, 1.88% respectively, P<0.001). The age-standardized death rate, age-standardized YLL rate and age-standardized DALY rate showed an decreasing trend (AAPC values were -0.37%, -0.84%, -0.81% respectively, P<0.001). The incidence of CNS tumors in the older age group increased from 1990 to 2019 (AAPC=1.02%, P＜0.001). The incidence rate in the younger group changed greatly, with a downward trend from 1999 to 2004 (APC=-4.79%, P<0.001), but an upward trend from 2007 to 2010 and 2013 to 2019 (APC were 4.13%, 1.47% respectively, P<0.001). Conclusion Disability status of CNS cancer has become an increasingly serious part of Chinese health care burden in recent years. In addition to improving the diagnosis and treatment technology of CNS cancer, we need to pay more attention to the research on the etiology of CNS cancer and formulate preventive and intervention measures for the high-risk age groups of CNS cancer.